Orphan Disease

© Getty Images

Acasti appoints WuXi to oversee STRIVE-ON trial

By Isabel Cameron

Acasti Pharma, a late-stage biopharma company with drug candidates addressing rare and orphan diseases, has selected WuXi Clinical Development to conduct its STRIVE-ON phase 3 safety trial for GTX-104, a novel injectable nimodipine formulation for intravenous...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All